Change language dansk English suomi svenska

Generate Estimates Confirm Cancel Hide empty rows Show hidden rows DummyText

SIMULPHARMA ApS Estimate generation in progress, please wait... 0%

Quicksearch from your own companies XBRLDenmark Analyst: XBRLDenmark

Loading... Loading... Loading... Loading... Loading... Loading... Loading...

1000.0 Bankruptcy Risk  2018 2018/12 2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024e N/A 2025e N/A Bankruptcy risk for industry   1.3% 1.3% 1.3% 1.3% 1.3% 1.3% 1.3% 1.3%   Bankruptcy risk   17.4% 14.8% 19.7% 21.8% 19.8% 31.4% 15.3% 15.2%   Credit score (0-100)   10 15 6 4 5 0 13 13   Credit rating   B BB B B B C BB BB   Credit limit (kDKK)   0.0 0.0 0.0 0.0 0.0 0.0 -0.0 -0.0   How are these values calculated?   View the automatically generated explanation of bankruptcy risk 1000.0 Income statement (kDKK)  2018 2018/12 2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024e N/A 2025e N/A Net sales   958 905 719 636 484 115 115 115   Gross profit   39.0 905 719 636 406 115 0.0 0.0   EBITDA   39.0 -15.0 43.0 -84.0 -58.0 -57.3 0.0 0.0   EBIT   39.0 -15.0 43.0 -84.0 -58.0 -57.3 0.0 0.0   Pre-tax profit (PTP)   39.0 -15.0 43.0 -85.0 -58.0 -57.3 0.0 0.0   Net earnings   30.0 -13.0 37.0 -83.0 -58.0 -57.3 0.0 0.0   Pre-tax profit without non-rec. items   39.0 -15.0 43.0 -85.0 -58.0 -57.3 0.0 0.0     See the entire income statement 1000.0 Balance sheet (kDKK)  2018 2018/12 2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024e N/A 2025e N/A Tangible assets total   0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0   Shareholders equity total   197 185 222 138 80.0 22.5 -57.5 -57.5   Interest-bearing liabilities   0.0 26.0 0.0 0.0 0.0 0.0 57.5 57.5   Balance sheet total (assets)   229 211 245 138 90.0 22.5 0.0 0.0   Net Debt   -222 -95.0 -230 -138 -90.0 -22.5 57.5 57.5     See the entire balance sheet 1000.0 Volume  2018 2018/12 2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024e N/A 2025e N/A Net sales   958 905 719 636 484 115 115 115   Net sales growth   -3.0% -5.5% -20.6% -11.5% -23.9% -76.2% 0.0% 0.0%   Gross profit   39.0 905 719 636 406 115 0.0 0.0   Gross profit growth   -96.0% 2,220.5% -20.6% -11.5% -36.2% -71.7% -100.0% 0.0%   Employees   0 0 0 0 0 1 0 0   Employee growth %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% -100.0% 0.0%   Employee expenses   0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0   Balance sheet total (assets)   229 211 245 138 90 22 0 0   Balance sheet change%   18.0% -7.9% 16.1% -43.7% -34.8% -75.0% -100.0% 0.0%   Added value   39.0 -15.0 43.0 -84.0 -58.0 -57.3 0.0 0.0   Added value %   4.1% -1.7% 6.0% -13.2% -12.0% -49.9% 0.0% 0.0%   Investments   0 0 0 0 0 0 0 0   Net sales trend   -2.0 -3.0 -4.0 -5.0 -5.0 -5.0 0.0 0.0   EBIT trend   3.0 -1.0 1.0 -1.0 -2.0 -3.0 0.0 0.0   1000.0 Profitability  2018 2018/12 2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024e N/A 2025e N/A EBITDA %   4.1% -1.7% 6.0% -13.2% -12.0% -49.9% 0.0% 0.0%   EBIT %   4.1% -1.7% 6.0% -13.2% -12.0% -49.9% 0.0% 0.0%   EBIT to gross profit (%)   100.0% -1.7% 6.0% -13.2% -14.3% -49.9% 0.0% 0.0%   Net Earnings %   3.1% -1.4% 5.1% -13.1% -12.0% -49.9% 0.0% 0.0%   Profit before depreciation and extraordinary items %   3.1% -1.4% 5.1% -13.1% -12.0% -49.9% 0.0% 0.0%   Pre tax profit less extraordinaries %   4.1% -1.7% 6.0% -13.4% -12.0% -49.9% 0.0% 0.0%   ROA %   18.4% -6.8% 18.9% -43.9% -50.9% -102.0% 0.0% 0.0%   ROI %   21.4% -7.4% 19.9% -46.7% -53.2% -111.9% 0.0% 0.0%   ROE %   16.5% -6.8% 18.2% -46.1% -53.2% -111.9% 0.0% 0.0%   1000.0 Solidity  2018 2018/12 2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024e N/A 2025e N/A Equity ratio %   86.0% 87.7% 90.6% 100.0% 88.9% 100.0% -100.0% -100.0%   Relative indebtedness %   3.3% 2.9% 3.2% 0.0% 2.1% 0.0% 50.0% 50.0%   Relative net indebtedness %   -19.8% -10.5% -28.8% -21.7% -16.5% -19.5% 50.0% 50.0%   Net int. bear. debt to EBITDA, %   -569.2% 633.3% -534.9% 164.3% 155.2% 39.2% 0.0% 0.0%   Gearing %   0.0% 14.1% 0.0% 0.0% 0.0% 0.0% -100.0% -100.0%   Net interest   0 0 0 0 0 0 0 0   Financing costs %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   1000.0 Liquidity  2018 2018/12 2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024e N/A 2025e N/A Quick Ratio   7.2 8.1 10.7 0.0 9.0 0.0 0.0 0.0   Current Ratio   7.2 8.1 10.7 0.0 9.0 0.0 0.0 0.0   Cash and cash equivalent   222.0 121.0 230.0 138.0 90.0 22.5 0.0 0.0   1000.0 Capital use efficiency  2018 2018/12 2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024e N/A 2025e N/A Trade debtors turnover (days)   0.0 28.6 0.0 0.0 0.0 0.0 0.0 0.0   Trade creditors turnover (days)   0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0   Current assets / Net sales %   23.9% 23.3% 34.1% 21.7% 18.6% 19.5% 0.0% 0.0%   Net working capital   197.0 185.0 222.0 138.0 80.0 22.5 -28.8 -28.8   Net working capital %   20.6% 20.4% 30.9% 21.7% 16.5% 19.5% -25.0% -25.0%   1000.0 Employee efficiency  2018 2018/12 2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024e N/A 2025e N/A Net sales / employee   0 0 0 0 0 115 0 0   Added value / employee   0 0 0 0 0 -57 0 0   Employee expenses / employee   0 0 0 0 0 0 0 0   EBITDA / employee   0 0 0 0 0 -57 0 0   EBIT / employee   0 0 0 0 0 -57 0 0   Net earnings / employee   0 0 0 0 0 -57 0 0